论文部分内容阅读
目的比较低分子肝素钠与常规华法林维持治疗恶性肿瘤合并深静脉血栓患者的疗效。方法选取2012年1月至2012年12月间收治的84例恶性肿瘤合并深静脉血栓患者,按照随机数字表法分为观察组和对照组,每组42例。观察组患者采用低分子肝素钠治疗,对照组患者采用常规华法林治疗。观察两组患者临床疗效、症状改善情况和深静脉血栓复发率。结果观察组患者总有效率为73.8%,对照组为52.4%,差异有统计学意义(P<0.05)。治疗后两组患者活化部分凝血活酶时间(APTT)及血浆凝血酶原时间(PT)均明显延长,但观察组患者延长时间明显优于对照组,组间差异有统计学意义(P<0.05)。观察组患者临床症状大多在2周内明显者改善,优于对照组,组间差异有统计学意义(P<0.05)。随访1年后,观察组患者深静脉血栓复发率为6.5%,显著低于对照组的22.7%,组间差异有统计学意义(P<0.05)。结论与华法林相比,低分子肝素钠维持治疗恶性肿瘤合并深静脉血栓患者疗效显著,用药方便、安全。
Objective To compare the efficacy of low molecular weight heparin with conventional warfarin in the maintenance of malignant tumor complicated with deep vein thrombosis. Methods Eighty-four patients with malignant tumor complicated with deep venous thrombosis admitted from January 2012 to December 2012 were divided into observation group and control group according to the random number table method, with 42 cases in each group. The observation group patients treated with low molecular weight heparin, the control group of patients treated with conventional warfarin. Clinical efficacy, symptom improvement and deep venous thrombosis recurrence rate were observed in two groups. Results The total effective rate was 73.8% in observation group and 52.4% in control group, the difference was statistically significant (P <0.05). After treatment, the activated partial thromboplastin time (APTT) and plasma prothrombin time (PT) in both groups were significantly prolonged, but the prolongation time in the observation group was significantly better than that in the control group, the difference was statistically significant (P <0.05 ). Clinical symptoms in observation group mostly improved obviously within 2 weeks, which was better than that of control group. There was significant difference between groups (P <0.05). One year after follow-up, the recurrence rate of deep venous thrombosis in observation group was 6.5%, which was significantly lower than that in control group (22.7%). There was significant difference between two groups (P <0.05). Conclusion Compared with warfarin, low molecular weight heparin maintenance treatment of malignant tumor patients with deep venous thrombosis significant effect, medication convenient and safe.